Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Turcot syndrome 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 35Carboplatin 24Specimen Handling 20Cyclophosphamide 18Magnetic Resonance Spectroscopy 17fludarabine 15Nivolumab 14Dexamethasone 14Bevacizumab 14Gemcitabine 12Biopsy 12atezolizumab 11Temozolomide 11Paclitaxel 10venetoclax 9Pemetrexed 9Ipilimumab 9Docetaxel 9Cisplatin 9Rituximab 8Lenalidomide 8blinatumomab 7Prednisone 7Oxaliplatin 7Fluorouracil 7Capecitabine 7olaparib 6lenvatinib 6Vincristine 6Radiotherapy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × denileukin diftitox × 30 days × Clear all
NCT05200559 2026-05-29

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

University of Pittsburgh

Phase 1/2 Active not recruiting
25 enrolled
Gynecologic

Turcot syndrome, Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡